DUBLIN--(BUSINESS WIRE)--The "Europe Biosimilar Insulin Glargine & Lispro Market, By End User (Type 1 Diabetes and Type 2 Diabetes),By Country (Germany, United Kingdom, France, Italy, Spain, Russia, ...

This week, the FDA approved LYUMJEV (insulin lispro-aabc), a new insulin lispro product by Lilly. LYUMJEV is a formulation of insulin lispro, developed to speed the absorption of insulin into the ...

LYON, France--(BUSINESS WIRE)-- Regulatory News: Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC, the “Company”), the biopharmaceutical company focused on the treatment of diabetes and other ...

MUNICH — Investigational technology (BioChaperone, Adocia) that enhances the action of already-approved off-patent insulins could improve glycemic control in patients with type 1 and type 2 diabetes, ...

INDIANAPOLIS, June 15, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Lyumjev™ (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), Eli Lilly and Company's ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a novel, faster-acting insulin lispro injection to improve glycemic response in adults with ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved an expanded label for rapid-acting insulin lispro-aabc injection to include administration via ...

This study is led by Prof. Weiping Jia (Department of Endocrinology and Metabolism, Shanghai Jiao Tong University School of Medicine Affiliated Sixth People’s Hospital). Despite the range of available ...

The US Food and Drug Administration has approved rapid-acting insulin lispro-aabc injection 100 and 200 units/mL (Lyumjev, Eli Lilly) for the treatment of adults with type 1 and type 2 diabetes. The ...

About The Study: In people with inadequately controlled type 2 diabetes treated with basal insulin in this randomized clinical trial with 1,428 participants, weekly tirzepatide compared with prandial ...

With drugmakers facing renewed calls to lower the cost of prescription drugs, Eli Lilly has taken preemptive action, dropping the cost of its generic insulin by 40%. Starting next year, Lilly’s list ...

Non inferior HbA1c reduction at 26 weeks (primary endpoint) Significant reduction of the rise of blood glucose after a test meal (key secondary endpoint) Blood glucose level, monitored by 10-point ...